Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
CAMBRIDGE, Mass., April 18, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2017 before the U.S. financial markets open on Tuesday, May 2, 2017.
Management will host a conference call on that date at 10:00 a.m. EDT to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 9265541. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
